Keywords
Last Name
Institution

Brian Walker

TitleProfessor
InstitutionUniversity of Arkansas for Medical Sciences
DepartmentMyeloma Genetics, College of Myeloma Institute
DivisionMyeloma Genetics I
Address4104 Outpatient Circle
Mail Slot # 816
Little Rock AR 72205
Phone501-526-6990
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Dr. Walker’s research is focused on the genetics of multiple myeloma. He is interested in the structure of the myeloma genome, from single nucleotide mutations to large structural events, such as translocations, and how these affect patients’ prognosis. Using cutting edge technologies he has investigated how these events change during the progression of disease from MGUS and asymptomatic myeloma through to myeloma and extramedullary disease. Dr. Walker has a keen interest in how these abnormalities drive the pathogenesis of high risk myeloma, initiating evolution of disease through intraclonal heterogeneity and drug resistance. His team is involved with implementing new genetic discoveries in the clinic through the use of innovative diagnostic tests.


    Collapse Affiliation 
    Collapse member of
    American Society of Hematology
    UK Myeloma Forum

    Collapse Research Funds 

    Collapse Outreach 

    Collapse Bibliographic 
    Collapse additional bibliographic sources
    The links below are provided by the researcher to provide access to external online bibliographies that they keep independently from the Profiles System.
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Thanendrarajan S, Tian E, Qu P, Mathur P, Schinke C, van Rhee F, Zangari M, Rasche L, Weinhold N, Alapat D, Bellamy W, Ashby C, Mattox S, Epstein J, Yaccoby S, Barlogie B, Hoering A, Bauer M, Walker BA, Davies FE, Morgan GJ. The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma. Haematologica. 2017 Sep; 102(9):e364-e367. PMID: 28550191.
      View in: PubMed
    2. Mikulasova A, Wardell CP, Murison A, Boyle EM, Jackson GH, Smetana J, Kufova Z, Pour L, Sandecka V, Almasi M, Vsianska P, Gregora E, Kuglik P, Hajek R, Davies FE, Morgan GJ, Walker BA. The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma. Haematologica. 2017 Sep; 102(9):1617-1625. PMID: 28550183.
      View in: PubMed
    3. Schinke C, Hoering A, Wang H, Carlton V, Thanandrarajan S, Deshpande S, Patel P, Molnar G, Susanibar S, Mohan M, Mathur P, Radhakrishnan M, Hoque S, Jo Kamimoto J, Grazziutti M, van Rhee F, Zangari M, Insuasti-Beltran G, Alapat D, Post G, Yaccoby S, Epstein J, Rasche L, Johnson S, Moorhead M, Willis T, Barlogie B, Walker B, Weinhold N, Davies FE, Morgan GJ. The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype. Haematologica. 2017 Aug; 102(8):e313-e316. PMID: 28522572.
      View in: PubMed
    4. Wren D, Walker BA, Brüggemann M, Catherwood MA, Pott C, Stamatopoulos K, Langerak AW, Gonzalez D. Comprehensive translocation and clonality detection in lymphoproliferative disorders by next-generation sequencing. Haematologica. 2017 Feb; 102(2):e57-e60. PMID: 27846615.
      View in: PubMed
    5. Weinhold N, Ashby C, Rasche L, Chavan SS, Stein C, Stephens OW, Tytarenko R, Bauer MA, Meissner T, Deshpande S, Patel PH, Buzder T, Molnar G, Peterson EA, van Rhee F, Zangari M, Thanendrarajan S, Schinke C, Tian E, Epstein J, Barlogie B, Davies FE, Heuck CJ, Walker BA, Morgan GJ. Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. Blood. 2016 Sep 29; 128(13):1735-44. PMID: 27516441.
      View in: PubMed
    6. Mitchell JS, Li N, Weinhold N, Försti A, Ali M, van Duin M, Thorleifsson G, Johnson DC, Chen B, Halvarsson BM, Gudbjartsson DF, Kuiper R, Stephens OW, Bertsch U, Broderick P, Campo C, Einsele H, Gregory WA, Gullberg U, Henrion M, Hillengass J, Hoffmann P, Jackson GH, Johnsson E, Jöud M, Kristinsson SY, Lenhoff S, Lenive O, Mellqvist UH, Migliorini G, Nahi H, Nelander S, Nickel J, Nöthen MM, Rafnar T, Ross FM, da Silva Filho MI, Swaminathan B, Thomsen H, Turesson I, Vangsted A, Vogel U, Waage A, Walker BA, Wihlborg AK, Broyl A, Davies FE, Thorsteinsdottir U, Langer C, Hansson M, Kaiser M, Sonneveld P, Stefansson K, Morgan GJ, Goldschmidt H, Hemminki K, Nilsson B, Houlston RS. Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. Nat Commun. 2016 Jul 01; 7:12050. PMID: 27363682; PMCID: PMC4932178.
    7. Mikulasova A, Smetana J, Wayhelova M, Janyskova H, Sandecka V, Kufova Z, Almasi M, Jarkovsky J, Gregora E, Kessler P, Wrobel M, Walker BA, Wardell CP, Morgan GJ, Hajek R, Kuglik P. Genomewide profiling of copy-number alteration in monoclonal gammopathy of undetermined significance. Eur J Haematol. 2016 Dec; 97(6):568-575. PMID: 27157252.
      View in: PubMed
    8. Pawlyn C, Kaiser MF, Heuck C, Melchor L, Wardell CP, Murison A, Chavan SS, Johnson DC, Begum DB, Dahir NM, Proszek PZ, Cairns DA, Boyle EM, Jones JR, Cook G, Drayson MT, Owen RG, Gregory WM, Jackson GH, Barlogie B, Davies FE, Walker BA, Morgan GJ. The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma. Clin Cancer Res. 2016 Dec 01; 22(23):5783-5794. PMID: 27235425.
      View in: PubMed
    9. Wu SP, Pfeiffer RM, Ahn IE, Mailankody S, Sonneveld P, van Duin M, Munshi NC, Walker BA, Morgan G, Landgren O. Impact of Genes Highly Correlated with MMSET Myeloma on the Survival of Non-MMSET Myeloma Patients. Clin Cancer Res. 2016 Aug 15; 22(16):4039-44. PMID: 26847058.
      View in: PubMed
    10. Walker BA, Boyle EM, Wardell CP, Murison A, Begum DB, Dahir NM, Proszek PZ, Johnson DC, Kaiser MF, Melchor L, Aronson LI, Scales M, Pawlyn C, Mirabella F, Jones JR, Brioli A, Mikulasova A, Cairns DA, Gregory WM, Quartilho A, Drayson MT, Russell N, Cook G, Jackson GH, Leleu X, Davies FE, Morgan GJ. Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma. J Clin Oncol. 2015 Nov 20; 33(33):3911-20. PMID: 26282654.
      View in: PubMed
    11. Di Martino MT, Guzzi PH, Caracciolo D, Agnelli L, Neri A, Walker BA, Morgan GJ, Cannataro M, Tassone P, Tagliaferri P. Integrated analysis of microRNAs, transcription factors and target genes expression discloses a specific molecular architecture of hyperdiploid multiple myeloma. Oncotarget. 2015 Aug 07; 6(22):19132-47. PMID: 26056083; PMCID: PMC4662480.
    12. Smith EM, Zhang L, Walker BA, Davenport EL, Aronson LI, Krige D, Hooftman L, Drummond AH, Morgan GJ, Davies FE. The combination of HDAC and aminopeptidase inhibitors is highly synergistic in myeloma and leads to disruption of the NF?B signalling pathway. Oncotarget. 2015 Jul 10; 6(19):17314-27. PMID: 26015393; PMCID: PMC4627310.
    13. Moorcraft SY, Gonzalez D, Walker BA. Understanding next generation sequencing in oncology: A guide for oncologists. Crit Rev Oncol Hematol. 2015 Dec; 96(3):463-74. PMID: 26160606.
      View in: PubMed
    14. Walker BA, Wardell CP, Murison A, Boyle EM, Begum DB, Dahir NM, Proszek PZ, Melchor L, Pawlyn C, Kaiser MF, Johnson DC, Qiang YW, Jones JR, Cairns DA, Gregory WM, Owen RG, Cook G, Drayson MT, Jackson GH, Davies FE, Morgan GJ. APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat Commun. 2015 Apr 23; 6:6997. PMID: 25904160; PMCID: PMC4568299.
    15. Weinhold N, Meissner T, Johnson DC, Seckinger A, Moreaux J, Försti A, Chen B, Nickel J, Chubb D, Rawstron AC, Doughty C, Dahir NB, Begum DB, Young K, Walker BA, Hoffmann P, Nöthen MM, Davies FE, Klein B, Goldschmidt H, Morgan GJ, Houlston RS, Hose D, Hemminki K. The 7p15.3 (rs4487645) association for multiple myeloma shows strong allele-specific regulation of the MYC-interacting gene CDCA7L in malignant plasma cells. Haematologica. 2015 Mar; 100(3):e110-3. PMID: 25480495; PMCID: PMC4349291.
    16. Pawlyn C, Melchor L, Murison A, Wardell CP, Brioli A, Boyle EM, Kaiser MF, Walker BA, Begum DB, Dahir NB, Proszek P, Gregory WM, Drayson MT, Jackson GH, Ross FM, Davies FE, Morgan GJ. Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations. Blood. 2015 Jan 29; 125(5):831-40. PMID: 25428216; PMCID: PMC4327151.
    17. Tornatore L, Sandomenico A, Raimondo D, Low C, Rocci A, Tralau-Stewart C, Capece D, D'Andrea D, Bua M, Boyle E, van Duin M, Zoppoli P, Jaxa-Chamiec A, Thotakura AK, Dyson J, Walker BA, Leonardi A, Chambery A, Driessen C, Sonneveld P, Morgan G, Palumbo A, Tramontano A, Rahemtulla A, Ruvo M, Franzoso G. Cancer-selective targeting of the NF-?B survival pathway with GADD45ß/MKK7 inhibitors. Cancer Cell. 2014 Oct 13; 26(4):495-508. PMID: 25314077; PMCID: PMC4197335.
    18. Boyle EM, Proszek PZ, Kaiser MF, Begum D, Dahir N, Savola S, Wardell CP, Leleu X, Ross FM, Chiecchio L, Cook G, Drayson MT, Owen RG, Ashcroft JM, Jackson GH, Anthony Child J, Davies FE, Walker BA, Morgan GJ. A molecular diagnostic approach able to detect the recurrent genetic prognostic factors typical of presenting myeloma. Genes Chromosomes Cancer. 2015 Feb; 54(2):91-8. PMID: 25287954; PMCID: PMC4310140.
    19. Brioli A, Melchor L, Walker BA, Davies FE, Morgan GJ. Biology and treatment of myeloma. Clin Lymphoma Myeloma Leuk. 2014 Sep; 14 Suppl:S65-70. PMID: 25486959.
      View in: PubMed
    20. Wu P, Walker BA, Broyl A, Kaiser M, Johnson DC, Kuiper R, van Duin M, Gregory WM, Davies FE, Brewer D, Hose D, Sonneveld P, Morgan GJ. A gene expression based predictor for high risk myeloma treated with intensive therapy and autologous stem cell rescue. Leuk Lymphoma. 2015 Mar; 56(3):594-601. PMID: 24913504; PMCID: PMC4444991.
    21. Mirabella F, Murison A, Aronson LI, Wardell CP, Thompson AJ, Hanrahan SJ, Fok JH, Pawlyn C, Kaiser MF, Walker BA, Davies FE, Morgan GJ. A novel functional role for MMSET in RNA processing based on the link between the REIIBP isoform and its interaction with the SMN complex. PLoS One. 2014; 9(6):e99493. PMID: 24923560; PMCID: PMC4055699.
    22. Walker BA, Wardell CP, Brioli A, Boyle E, Kaiser MF, Begum DB, Dahir NB, Johnson DC, Ross FM, Davies FE, Morgan GJ. Translocations at 8q24 juxtapose MYC with genes that harbor superenhancers resulting in overexpression and poor prognosis in myeloma patients. Blood Cancer J. 2014 Mar 14; 4:e191. PMID: 24632883; PMCID: PMC3972699.
    23. Weinhold N, Johnson DC, Rawstron AC, Försti A, Doughty C, Vijayakrishnan J, Broderick P, Dahir NB, Begum DB, Hosking FJ, Yong K, Walker BA, Hoffmann P, Mühleisen TW, Langer C, Dörner E, Jöckel KH, Eisele L, Nöthen MM, Hose D, Davies FE, Goldschmidt H, Morgan GJ, Hemminki K, Houlston RS. Inherited genetic susceptibility to monoclonal gammopathy of unknown significance. Blood. 2014 Apr 17; 123(16):2513-7; quiz 2593. PMID: 24449210.
      View in: PubMed
    24. Melchor L, Brioli A, Wardell CP, Murison A, Potter NE, Kaiser MF, Fryer RA, Johnson DC, Begum DB, Hulkki Wilson S, Vijayaraghavan G, Titley I, Cavo M, Davies FE, Walker BA, Morgan GJ. Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma. Leukemia. 2014 Aug; 28(8):1705-15. PMID: 24480973.
      View in: PubMed
    25. Chubb D, Weinhold N, Broderick P, Chen B, Johnson DC, Försti A, Vijayakrishnan J, Migliorini G, Dobbins SE, Holroyd A, Hose D, Walker BA, Davies FE, Gregory WA, Jackson GH, Irving JA, Pratt G, Fegan C, Fenton JA, Neben K, Hoffmann P, Nöthen MM, Mühleisen TW, Eisele L, Ross FM, Straka C, Einsele H, Langer C, Dörner E, Allan JM, Jauch A, Morgan GJ, Hemminki K, Houlston RS, Goldschmidt H. Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk. Nat Genet. 2013 Oct; 45(10):1221-1225. PMID: 23955597.
      View in: PubMed
    26. Walker BA, Wardell CP, Melchor L, Brioli A, Johnson DC, Kaiser MF, Mirabella F, Lopez-Corral L, Humphray S, Murray L, Ross M, Bentley D, Gutiérrez NC, Garcia-Sanz R, San Miguel J, Davies FE, Gonzalez D, Morgan GJ. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia. 2014 Feb; 28(2):384-390. PMID: 23817176; PMCID: PMC3916874.
    27. Walker BA, Wardell CP, Ross FM, Morgan GJ. Identification of a novel t(7;14) translocation in multiple myeloma resulting in overexpression of EGFR. Genes Chromosomes Cancer. 2013 Sep; 52(9):817-22. PMID: 23765574.
      View in: PubMed
    28. Wu P, Agnelli L, Walker BA, Todoerti K, Lionetti M, Johnson DC, Kaiser M, Mirabella F, Wardell C, Gregory WM, Davies FE, Brewer D, Neri A, Morgan GJ. Improved risk stratification in myeloma using a microRNA-based classifier. Br J Haematol. 2013 Aug; 162(3):348-59. PMID: 23718138.
      View in: PubMed
    29. Kaiser MF, Johnson DC, Wu P, Walker BA, Brioli A, Mirabella F, Wardell CP, Melchor L, Davies FE, Morgan GJ. Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma. Blood. 2013 Jul 11; 122(2):219-26. PMID: 23699600; PMCID: PMC3709654.
    30. Mirabella F, Wu P, Wardell CP, Kaiser MF, Walker BA, Johnson DC, Morgan GJ. MMSET is the key molecular target in t(4;14) myeloma. Blood Cancer J. 2013 May 03; 3:e114. PMID: 23645128; PMCID: PMC3674460.
    31. Weinhold N, Johnson DC, Chubb D, Chen B, Försti A, Hosking FJ, Broderick P, Ma YP, Dobbins SE, Hose D, Walker BA, Davies FE, Kaiser MF, Li NL, Gregory WA, Jackson GH, Witzens-Harig M, Neben K, Hoffmann P, Nöthen MM, Mühleisen TW, Eisele L, Ross FM, Jauch A, Goldschmidt H, Houlston RS, Morgan GJ, Hemminki K. The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma. Nat Genet. 2013 May; 45(5):522-525. PMID: 23502783.
      View in: PubMed
    32. Walker BA, Wardell CP, Johnson DC, Kaiser MF, Begum DB, Dahir NB, Ross FM, Davies FE, Gonzalez D, Morgan GJ. Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells. Blood. 2013 Apr 25; 121(17):3413-9. PMID: 23435460.
      View in: PubMed
    33. Kaiser MF, Walker BA, Hockley SL, Begum DB, Wardell CP, Gonzalez D, Ross FM, Davies FE, Morgan GJ. A TC classification-based predictor for multiple myeloma using multiplexed real-time quantitative PCR. Leukemia. 2013 Aug; 27(8):1754-7. PMID: 23318961.
      View in: PubMed
    34. Walker BA, Wardell CP, Melchor L, Hulkki S, Potter NE, Johnson DC, Fenwick K, Kozarewa I, Gonzalez D, Lord CJ, Ashworth A, Davies FE, Morgan GJ. Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. Blood. 2012 Aug 02; 120(5):1077-86. PMID: 22573403.
      View in: PubMed
    35. Morgan GJ, Walker BA, Davies FE. The genetic architecture of multiple myeloma. Nat Rev Cancer. 2012 Apr 12; 12(5):335-48. PMID: 22495321.
      View in: PubMed
    36. Broderick P, Chubb D, Johnson DC, Weinhold N, Försti A, Lloyd A, Olver B, Ma Y, Dobbins SE, Walker BA, Davies FE, Gregory WA, Childs JA, Ross FM, Jackson GH, Neben K, Jauch A, Hoffmann P, Mühleisen TW, Nöthen MM, Moebus S, Tomlinson IP, Goldschmidt H, Hemminki K, Morgan GJ, Houlston RS. Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk. Nat Genet. 2011 Nov 27; 44(1):58-61. PMID: 22120009.
      View in: PubMed
    37. Kassambara A, Hose D, Moreaux J, Walker BA, Protopopov A, Reme T, Pellestor F, Pantesco V, Jauch A, Morgan G, Goldschmidt H, Klein B. Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma. Haematologica. 2012 Apr; 97(4):622-30. PMID: 22102711; PMCID: PMC3347668.
    38. Boyd KD, Ross FM, Walker BA, Wardell CP, Tapper WJ, Chiecchio L, Dagrada G, Konn ZJ, Gregory WM, Jackson GH, Child JA, Davies FE, Morgan GJ. Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival. Clin Cancer Res. 2011 Dec 15; 17(24):7776-84. PMID: 21994415.
      View in: PubMed
    39. Boyd KD, Ross FM, Tapper WJ, Chiecchio L, Dagrada G, Konn ZJ, Gonzalez D, Walker BA, Hockley SL, Wardell CP, Gregory WM, Child JA, Jackson GH, Davies FE, Morgan GJ. The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy. Genes Chromosomes Cancer. 2011 10; 50(10):765-74. PMID: 21961181.
      View in: PubMed
    40. Agnelli L, Forcato M, Ferrari F, Tuana G, Todoerti K, Walker BA, Morgan GJ, Lombardi L, Bicciato S, Neri A. The reconstruction of transcriptional networks reveals critical genes with implications for clinical outcome of multiple myeloma. Clin Cancer Res. 2011 Dec 01; 17(23):7402-12. PMID: 21890453.
      View in: PubMed
    41. Wu P, Walker BA, Brewer D, Gregory WM, Ashcroft J, Ross FM, Jackson GH, Child AJ, Davies FE, Morgan GJ. A gene expression-based predictor for myeloma patients at high risk of developing bone disease on bisphosphonate treatment. Clin Cancer Res. 2011 Oct 01; 17(19):6347-55. PMID: 21856767; PMCID: PMC3866998.
    42. Boyd KD, Ross FM, Chiecchio L, Dagrada GP, Konn ZJ, Tapper WJ, Walker BA, Wardell CP, Gregory WM, Szubert AJ, Bell SE, Child JA, Jackson GH, Davies FE, Morgan GJ. A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia. 2012 Feb; 26(2):349-55. PMID: 21836613; PMCID: PMC4545515.
    43. Boyd KD, Ross FM, Chiecchio L, Dagrada G, Konn ZJ, Tapper WJ, Walker BA, Wardell CP, Gregory WM, Szubert AJ, Davies FE, Morgan GJ. Gender disparities in the tumor genetics and clinical outcome of multiple myeloma. Cancer Epidemiol Biomarkers Prev. 2011 Aug; 20(8):1703-7. PMID: 21680536; PMCID: PMC4545514.
    44. Walker BA, Hunt LG, Sowa AK, Skjødt K, Göbel TW, Lehner PJ, Kaufman J. The dominantly expressed class I molecule of the chicken MHC is explained by coevolution with the polymorphic peptide transporter (TAP) genes. Proc Natl Acad Sci U S A. 2011 May 17; 108(20):8396-401. PMID: 21536896; PMCID: PMC3100931.
    45. Walker BA, Morgan GJ. Could DNA methylation become a useful measure for multiple myeloma prognoses? Expert Rev Hematol. 2011 Apr; 4(2):125-7. PMID: 21495920.
      View in: PubMed
    46. Hockley SL, Morgan GJ, Leone PE, Walker BA, Morilla A, Else M, Wotherspoon A, Dearden C, Catovsky D, Gonzalez D, Matutes E. High-resolution genomic profiling in hairy cell leukemia-variant compared with typical hairy cell leukemia. Leukemia. 2011 Jul; 25(7):1189-92. PMID: 21436839.
      View in: PubMed
    47. Johnson DC, Corthals SL, Walker BA, Ross FM, Gregory WM, Dickens NJ, Lokhorst HM, Goldschmidt H, Davies FE, Durie BG, Van Ness B, Child JA, Sonneveld P, Morgan GJ. Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. J Clin Oncol. 2011 Mar 01; 29(7):797-804. PMID: 21245421.
      View in: PubMed
    48. Walker BA, Wardell CP, Chiecchio L, Smith EM, Boyd KD, Neri A, Davies FE, Ross FM, Morgan GJ. Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. Blood. 2011 Jan 13; 117(2):553-62. PMID: 20944071.
      View in: PubMed
    49. Boyd KD, Walker BA, Wardell CP, Ross FM, Gregory WM, Davies FE, Morgan GJ. High expression levels of the mammalian target of rapamycin inhibitor DEPTOR are predictive of response to thalidomide in myeloma. Leuk Lymphoma. 2010 Nov; 51(11):2126-9. PMID: 20858096.
      View in: PubMed
    50. Walker BA, Leone PE, Chiecchio L, Dickens NJ, Jenner MW, Boyd KD, Johnson DC, Gonzalez D, Dagrada GP, Protheroe RK, Konn ZJ, Stockley DM, Gregory WM, Davies FE, Ross FM, Morgan GJ. A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. Blood. 2010 Oct 14; 116(15):e56-65. PMID: 20616218.
      View in: PubMed
    51. Bagratuni T, Wu P, Gonzalez de Castro D, Davenport EL, Dickens NJ, Walker BA, Boyd K, Johnson DC, Gregory W, Morgan GJ, Davies FE. XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments. Blood. 2010 Jul 15; 116(2):250-3. PMID: 20421453.
      View in: PubMed
    52. Dickens NJ, Walker BA, Leone PE, Johnson DC, Brito JL, Zeisig A, Jenner MW, Boyd KD, Gonzalez D, Gregory WM, Ross FM, Davies FE, Morgan GJ. Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome. Clin Cancer Res. 2010 Mar 15; 16(6):1856-64. PMID: 20215539; PMCID: PMC2841345.
    53. Moore HE, Davenport EL, Smith EM, Muralikrishnan S, Dunlop AS, Walker BA, Krige D, Drummond AH, Hooftman L, Morgan GJ, Davies FE. Aminopeptidase inhibition as a targeted treatment strategy in myeloma. Mol Cancer Ther. 2009 Apr; 8(4):762-70. PMID: 19372548.
      View in: PubMed
    54. Brito JL, Walker B, Jenner M, Dickens NJ, Brown NJ, Ross FM, Avramidou A, Irving JA, Gonzalez D, Davies FE, Morgan GJ. MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells. Haematologica. 2009 Jan; 94(1):78-86. PMID: 19059936; PMCID: PMC2625417.
    55. Leone PE, Walker BA, Jenner MW, Chiecchio L, Dagrada G, Protheroe RK, Johnson DC, Dickens NJ, Brito JL, Else M, Gonzalez D, Ross FM, Chen-Kiang S, Davies FE, Morgan GJ. Deletions of CDKN2C in multiple myeloma: biological and clinical implications. Clin Cancer Res. 2008 Oct 01; 14(19):6033-41. PMID: 18829482; PMCID: PMC2581792.
    56. Jenner MW, Leone PE, Walker BA, Ross FM, Johnson DC, Gonzalez D, Chiecchio L, Dachs Cabanas E, Dagrada GP, Nightingale M, Protheroe RK, Stockley D, Else M, Dickens NJ, Cross NC, Davies FE, Morgan GJ. Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. Blood. 2007 Nov 01; 110(9):3291-300. PMID: 17609426.
      View in: PubMed
    57. Walker BA, Morgan GJ. Use of single nucleotide polymorphism-based mapping arrays to detect copy number changes and loss of heterozygosity in multiple myeloma. Clin Lymphoma Myeloma. 2006 Nov; 7(3):186-91. PMID: 17229333.
      View in: PubMed
    58. Walker BA, Leone PE, Jenner MW, Li C, Gonzalez D, Johnson DC, Ross FM, Davies FE, Morgan GJ. Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. Blood. 2006 Sep 01; 108(5):1733-43. PMID: 16705090.
      View in: PubMed
    59. Walker BA, van Hateren A, Milne S, Beck S, Kaufman J. Chicken TAP genes differ from their human orthologues in locus organisation, size, sequence features and polymorphism. Immunogenetics. 2005 May; 57(3-4):232-47. PMID: 15900495.
      View in: PubMed
    60. Wong GK, Liu B, Wang J, Zhang Y, Yang X, Zhang Z, Meng Q, Zhou J, Li D, Zhang J, Ni P, Li S, Ran L, Li H, Zhang J, Li R, Li S, Zheng H, Lin W, Li G, Wang X, Zhao W, Li J, Ye C, Dai M, Ruan J, Zhou Y, Li Y, He X, Zhang Y, Wang J, Huang X, Tong W, Chen J, Ye J, Chen C, Wei N, Li G, Dong L, Lan F, Sun Y, Zhang Z, Yang Z, Yu Y, Huang Y, He D, Xi Y, Wei D, Qi Q, Li W, Shi J, Wang M, Xie F, Wang J, Zhang X, Wang P, Zhao Y, Li N, Yang N, Dong W, Hu S, Zeng C, Zheng W, Hao B, Hillier LW, Yang SP, Warren WC, Wilson RK, Brandström M, Ellegren H, Crooijmans RP, van der Poel JJ, Bovenhuis H, Groenen MA, Ovcharenko I, Gordon L, Stubbs L, Lucas S, Glavina T, Aerts A, Kaiser P, Rothwell L, Young JR, Rogers S, Walker BA, van Hateren A, Kaufman J, Bumstead N, Lamont SJ, Zhou H, Hocking PM, Morrice D, de Koning DJ, Law A, Bartley N, Burt DW, Hunt H, Cheng HH, Gunnarsson U, Wahlberg P, Andersson L, Kindlund E, Tammi MT, Andersson B, Webber C, Ponting CP, Overton IM, Boardman PE, Tang H, Hubbard SJ, Wilson SA, Yu J, Wang J, Yang H. A genetic variation map for chicken with 2.8 million single-nucleotide polymorphisms. Nature. 2004 Dec 09; 432(7018):717-22. PMID: 15592405; PMCID: PMC2263125.
    61. Kaufman J, Milne S, Göbel TW, Walker BA, Jacob JP, Auffray C, Zoorob R, Beck S. The chicken B locus is a minimal essential major histocompatibility complex. Nature. 1999 Oct 28; 401(6756):923-5. PMID: 10553909.
      View in: PubMed
    62. Kaufman J, Jacob J, Shaw I, Walker B, Milne S, Beck S, Salomonsen J. Gene organisation determines evolution of function in the chicken MHC. Immunol Rev. 1999 Feb; 167:101-17. PMID: 10319254.
      View in: PubMed
    Walker's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _